Evidence map›Paper›PMID 36962290›Full record

ArticlePLOS global public health2022

COVID-19 mortality rate and its associated factors during the first and second waves in Nigeria.

Kelly Elimian, Anwar Musah, Carina King, Ehimario Igumbor, Puja Myles, Olaolu Aderinola, Cyril Erameh, William Nwanchukwu, Oluwatosin Akande, Ndembi Nicaise and 52 more

Full text read
In one paragraph

Article in PLOS global public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

62 authors.

Kelly ElimianNigeria Centre for Disease Control, Abuja, Nigeria.
Anwar MusahNigeria COVID-19 Research Coalition, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-7978-1871
Carina KingDepartment of Global Public Health, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-6885-6716
Ehimario IgumborNigeria Centre for Disease Control, Abuja, Nigeria.
Puja MylesClinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London, United Kingdom.ORCID https://orcid.org/0000-0002-8976-890X
Olaolu AderinolaNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-6496-6996
Cyril EramehInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.ORCID https://orcid.org/0000-0001-7783-2495
William NwanchukwuNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-7111-1320
Oluwatosin AkandeNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-6906-895X
Ndembi NicaiseAfrica Centres for Disease Control and Prevention, Addis-Ababa, Ethiopia.
Oladipo OgunbodeNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-8337-796X
Abiodun EgwuenuNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-9369-4771
Emily CrawfordNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-4645-5724
Giulia GaudenziDepartment of Global Public Health, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0003-4923-6965
Ismail Abdus-SalamLagos State Ministry of Health, Lagos, Lagos State, Nigeria.
Olubunmi OlophaNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-5950-1868
Yahya DisuNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-6310-2034
Abimbola BowaleInfectious Disease Unit, Mainland Hospital, Lagos, Lagos State, Nigeria.
Cyprian OshomaDepartment of Microbiology, Faculty of Life Sciences, University of Benin, Benin City, Edo State, Nigeria.
Cornelius OhonsiNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-4727-6835
Chinedu ArinzeNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-7452-1392
Sikiru BadaruNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-3035-2640
Blessing EbhodagheNigeria Centre for Disease Control, Abuja, Nigeria.
Zaiyad HabibUniversity of Abuja Teaching Hospital, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-9770-8747
Michael OlugbileThe World Bank, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-1096-5864
Chioma Dan-NwaforNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-3294-2276
Jafiya AbubakarNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-6173-2721
Emmanuel PembiAdamawa State Ministry of Health and Human Services, Yola, Adamawa State, Nigeria.
Lauryn DunkwuTony Blair Institute for Global Change, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-2350-7130
Ifeanyi IkeNigeria Centre for Disease Control, Abuja, Nigeria.
Ekaete TobinInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.ORCID https://orcid.org/0000-0001-5059-807X
Bamidele MutiuLagos State Biobank Mainland Hospital Yaba, Lagos, Lagos State, Nigeria.
Rejoice Luka-LawalNigeria Centre for Disease Control, Abuja, Nigeria.
Obinna NwaforNigeria Centre for Disease Control, Abuja, Nigeria.
Mildred OkowaMinistry of Health, Asaba, Delta State, Nigeria.
Chidiebere EzeokaforNigeria COVID-19 Research Coalition, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-6061-8780
Emem IwaraMaryland Global Initiatives Corporation, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-8826-1464
Sebastian YennanNigeria Centre for Disease Control, Abuja, Nigeria.
Sunday EziechinaNigeria Centre for Disease Control, Abuja, Nigeria.
David OlatunjiNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-2732-7794
Lanre FalodunDepartment of Internal Medicine, National Hospital, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-8116-6739
Emmanuel JosephKaduna State Infectious Disease Control Centre, Kaduna, Kaduna State, Nigeria.ORCID https://orcid.org/0000-0003-0440-2691
Ifeanyi AbaliNigeria Centre for Disease Control, Abuja, Nigeria.
Tarik MohammedNigeria Centre for Disease Control, Abuja, Nigeria.
Benjamin YigaBauchi State Ministry of Health, Bauchi, Bauchi State, Nigeria.
Khadeejah KamaldeenKwara State Ministry of Health, Ilorin, Kwara State, Nigeria.ORCID https://orcid.org/0000-0002-6132-6931
Emmanuel AgogoResolve to Save Lives, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-3570-3254
Nwando MbaNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-2998-2354
John OladejoNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-0156-1489
Elsie IloriNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-1731-2604
Olusola ArunaInternational Health Strengthening Project, Global Public Health, Public Health England, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-7879-634X
Geoffrey NamaraWorld Health Organization, Abuja, Nigeria.
Stephen ObaroDepartment of Paediatrics, University of Nebraska, Lincoln, Nebraska, United States of America.
Khadeejah HamzaNigeria COVID-19 Research Coalition, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-0811-2982
Michael AsuzuNigeria COVID-19 Research Coalition, Abuja, Nigeria.
Shaibu BelloNigeria COVID-19 Research Coalition, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-5380-5759
Friday OkonofuaCentre of Excellence in Reproductive Health Innovation, University of Benin, Benin City, Edo State, Nigeria.ORCID https://orcid.org/0000-0002-8777-2606
Yusuf DeeniNigeria COVID-19 Research Coalition, Abuja, Nigeria.
Ibrahim AbubakarInstitute for Global Health, Faculty of Pop Health Sciences, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-0370-1430
Tobias AlfvenDepartment of Global Public Health, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-2328-3512
Chinwe OchuNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-0630-7332
Chikwe IhekweazuNigeria Centre for Disease Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-0659-0833

Funding

World Health Organization 001
6 · The paper itself

Abstract

COVID-19 mortality rate has not been formally assessed in Nigeria. Thus, we aimed to address this gap and identify associated mortality risk factors during the first and second waves in Nigeria. This was a retrospective analysis of national surveillance data from all 37 States in Nigeria between February 27, 2020, and April 3, 2021. The outcome variable was mortality amongst persons who tested positive for SARS-CoV-2 by Reverse-Transcriptase Polymerase Chain Reaction. Incidence rates of COVID-19 mortality was calculated by dividing the number of deaths by total person-time (in days) contributed by the entire study population and presented per 100,000 person-days with 95% Confidence Intervals (95% CI). Adjusted negative binomial regression was used to identify factors associated with COVID-19 mortality. Findings are presented as adjusted Incidence Rate Ratios (aIRR) with 95% CI. The first wave included 65,790 COVID-19 patients, of whom 994 (1∙51%) died; the second wave included 91,089 patients, of whom 513 (0∙56%) died. The incidence rate of COVID-19 mortality was higher in the first wave [54∙25 (95% CI: 50∙98-57∙73)] than in the second wave [19∙19 (17∙60-20∙93)]. Factors independently associated with increased risk of COVID-19 mortality in both waves were: age ≥45 years, male gender [first wave aIRR 1∙65 (1∙35-2∙02) and second wave 1∙52 (1∙11-2∙06)], being symptomatic [aIRR 3∙17 (2∙59-3∙89) and 3∙04 (2∙20-4∙21)], and being hospitalised [aIRR 4∙19 (3∙26-5∙39) and 7∙84 (4∙90-12∙54)]. Relative to South-West, residency in the South-South and North-West was associated with an increased risk of COVID-19 mortality in both waves. In conclusion, the rate of COVID-19 mortality in Nigeria was higher in the first wave than in the second wave, suggesting an improvement in public health response and clinical care in the second wave. However, this needs to be interpreted with caution given the inherent limitations of the country's surveillance system during the study.

Identifiers

PMID36962290
PMCPMC10022313

What OpenQuestion holds

Textfull text, public
LicenceCC0
reference markers read1
measurements read35
identifiers read13
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.